Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.
Who will be affected?
Readers: No access to all 28 journals. We recommend accessing our articles via PubMed Central
Authors: No access to the submission form or your user account.
Reviewers: No access to your user account. Please download manuscripts you are reviewing for offline reading before Wednesday, July 01, 2020 at 7:00 PM.
Editors: No access to your user account to assign reviewers or make decisions.
Copyeditors: No access to user account. Please download manuscripts you are copyediting before Wednesday, July 01, 2020 at 7:00 PM.
Lin FC, Huang ST, Shang RJ, Wang CC, Hsiao FY, Lin FJ, Lin MS, Hung KY, Wang J, Shen LJ, Lai F, Huang CF
A Web-Based Clinical System for Cohort Surveillance of Specific Clinical Effectiveness and Safety Outcomes: A Cohort Study of Non–Vitamin K Antagonist Oral Anticoagulants and Warfarin
An Online Clinical System for Cohort Surveillance of Specific Clinical Effectiveness and Safety Outcomes: Example of Non-vitamin K Antagonist Oral Anticoagulants and Warfarin
Fong-Ci Lin;
Shih-Tsung Huang;
Rung-Ji Shang;
Chi-Chuan Wang;
Fei-Yuan Hsiao;
Fang-Ju Lin;
Mei-Shu Lin;
Kuan-Yu Hung;
Jui Wang;
Li-Jiuan Shen;
Feipei Lai;
Chih-Fen Huang
ABSTRACT
Background:
Active drug surveillance is the proactive process of assessing the adverse drug events (ADEs), but conventional systems lack a seamless workflow.
Objective:
This study aims to develop a seamless and online workflow for comparing the safety and effectiveness of drugs in a database of electronic medical records.
Methods:
We proposed a comprehensive integration process for clinical surveillance using the National Taiwan University Hospital Clinical Surveillance System (NCSS). We studied a practical application of the NCSS that evaluates the drug safety and effectiveness of novel oral-anticoagulants (NOACs) and warfarin by Cohort Tree Analysis in an efficient and interoperable platform.
Results:
We demonstrated a practical example of investigating the differences in effectiveness and safety between NOACs and warfarin in patients with non-valvular atrial fibrillation (AF) using the NCSS. We efficiently identified 2,357 non-valvular AF patients with newly prescribed oral anticoagulants between 2010 and 2015 and further developed one main cohort and two sub-cohorts for separately measuring ischemic stroke as the clinical effectiveness outcome and intracranial hemorrhage as the safety outcome. In the sub-cohort of ischemic stroke, NOACs users exhibited a significantly lower risk of ischemic stroke compared with warfarin users after adjusting for age, sex, comorbidity and co-medication in an intention-to-treat (ITT) analysis (P = 0.01) but exhibited a comparable risk in an as-treated (AT) analysis (P = 0.12) after the 2-year follow-up. In the sub-cohort of intracranial hemorrhage (ICH), NOACs users exhibited a comparable risk of ICH both in ITT (P = 0.68) and AT analyses (P = 0.15).
Conclusions:
With a seamless and online workflow, the NCSS can serve the critical role of forming associations between evidence and the real world at a medical center in Taiwan.
Citation
Please cite as:
Lin FC, Huang ST, Shang RJ, Wang CC, Hsiao FY, Lin FJ, Lin MS, Hung KY, Wang J, Shen LJ, Lai F, Huang CF
A Web-Based Clinical System for Cohort Surveillance of Specific Clinical Effectiveness and Safety Outcomes: A Cohort Study of Non–Vitamin K Antagonist Oral Anticoagulants and Warfarin